Diamide inhibitors of cytochrome P450

A method of reducing toxicity in a subject of a compound that is metabolized by cytochrome P450 monooxygenase to a toxic metabolite, comprising administering to said subject in need thereof an effective amount of a compound having the formula:

• wherein:
• m is 1-3;
• at least one of R1, R2, R3, R4, R5, and R6 is C1-C6 alkyl substituted with an otherwise unsubstituted benzofuran, wherein said alkyl is linked to the 4, 5, 6, or 7 position of the benzofuran;
• each R1, R2, R3, R4, R5, and R6 independently is selected from the group consisting of H optionally substituted C1-C8 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heterocyclo, optionally substituted heterocycloalkyl, and optionally substituted heterocycloalkylalkyl;
• where each optional substituent is independently selected from the group consisting of halo, —CN, —NO2, —COnR, —CON(R)2, —C(S)R, —C(S)N(R)2, —SOnN(R)2, —SR, —SOnR, —N(R)2,—N(R)COnR, —NRS(O)nR, —NRC[═N(R)]N(R)2, —N(R)N(R)COnR, —NRPOnN(R)2, —NRPOnOR, oxo, ═N—OR, ═N—N(R)2, ═NR, ═NNRC(O)N(R)2, ═NNRCOnR, ═NNRS(O)nN(R)2, ═NNRS(O)n(R)C1-C8 alkyl, OR, C1-C8 alkyl, C2 —C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, heterocyclo, aryl, and heteroaryl;
• each R is independently selected from the group consisting of:
• H, C1-C8 alkyl, C3-C8 cycloalkyl, cycloalkylalk, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclo, heterocycloalkyl, and heterocycloalkylalkyl;
• and
• each n is independently 1 or 2;
• or a stereoisomeric form or pharmacologically acceptable salt thereof;
• provided that at least two of R1, R2, R3, R4, R5, and R6 are not H;
• and
• provided that when R1 and R2 are isobutyl, R3 and R4 are H, and R5 is CH2-[5]-benzofuranyl, then R6 cannot be —CH2-4-pyridyl, —CH2-1,5-dimethyl-3-pyrazolyl, or —CH2-4-methyl-2-thiazolyl.